Aurobindo buys 80% of A1 Biochem for $13.6M to build integrated CRDMO

What's the deal? Apitoria Pharma, a wholly owned subsidiary of Aurobindo PharmaDealroom has a profile for this one. Try Dealroom →, is acquiring an 80% stake in A1 Biochem Group for $13.6 million. The transaction is structured on a debt-free, cash-free basis, subject to closing adjustments, and is expected to close within 90 to 120 days.

Who is A1 Biochem? The group is a contract research organisation specialising in custom synthesis, medicinal chemistry, and analytical development. It runs laboratories in the US and India, employing over 90 scientists and serving more than 50 clients.

A1 Biochem reported turnover of ₹106.22 crore in FY2024-25 and ₹102.44 crore in FY2025-26, with EBITDA of ₹46.55 crore in the latest year.

What's the endgame? Aurobindo wants to build an integrated Contract Research, Development and Manufacturing (CRDMO) platform. Combining A1 Biochem's research with Aurobindo's active pharmaceutical ingredient (API) manufacturing lets it serve customers across the full product lifecycle, from early-stage research to large-scale production.

What could go wrong? The final investment amount depends on closing adjustments, and completion hinges on customary regulatory approvals. Integrating the two businesses will also test the strategy.

The signal: The move reflects a broader trend of Indian pharmaceutical companies expanding into R&D and integrated manufacturing services to offer end-to-end solutions to global clients. Aurobindo is climbing the value chain rather than competing on manufacturing alone.

Read more: whalesbook.com

Image credit: Jefferson Lab